Kalaris Therapeutics, Inc.
KLRS
$5.54
$0.071.28%
NASDAQ
| 09/30/2025 | 06/30/2025 | 09/30/2024 | |||
|---|---|---|---|---|---|
| Net Income | -4.79% | -11.32% | -574.05% | ||
| Total Depreciation and Amortization | -- | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | ||
| Total Other Non-Cash Items | -4.06% | 165.02% | 6,286.67% | ||
| Change in Net Operating Assets | 99.49% | -175.87% | 788.95% | ||
| Cash from Operations | 9.62% | -68.51% | -8.96% | ||
| Capital Expenditure | -- | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -- | -- | -- | ||
| Total Debt Issued | -- | -100.00% | -100.00% | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -- | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -100.00% | 100.00% | ||
| Cash from Financing | -- | -100.00% | -99.98% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -267.17% | -112.56% | -527.47% | ||